Evidence map›Paper›PMID 23165243›Full record

ReviewCell cycle (Georgetown, Tex.)2012

p63 the guardian of human reproduction.

Ivano Amelio, Francesca Grespi, Margherita Annicchiarico-Petruzzelli, Gerry Melino

Open access · bronzeAbstract readReview
In one paragraph

Review in Cell cycle (Georgetown, Tex.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 63 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. The dual role of p63 in cancer.Frontiers in oncology · 2023
    Review
  9. Article
  10. Review
  11. The Role of Mutant p63 in Female Fertility.International journal of molecular sciences · 2021
    Review
  12. Review
  13. p63-related signaling at a glance.Journal of cell science · 2020
    Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 3 countries.

Ivano AmelioMedical Research Council, Toxicology Unit, Leicester University, Leicester, UK.
Francesca Grespi
Margherita Annicchiarico-Petruzzelli
Gerry Melino
University of Rome Tor Vergata · ITGhent University Hospital · BEMedical Research Council · GB

Funding

Medical Research Council MC_U132670600
6 · The paper itself

Abstract

p63 is a transcriptional factor implicated in cancer and development. The presence in TP63 gene of alternative promoters allows expression of one isoform containing the N-terminal transactivation domain (TA isoform) and one N-terminal truncated isoform (ΔN isoform). Complete ablation of all p63 isoforms produced mice with fatal developmental abnormalities, including lack of epidermal barrier, limbs and other epidermal appendages. Specific TAp63-null mice, although they developed normally, failed to undergo in DNA damage-induced apoptosis during primordial follicle meiotic arrest, suggesting a p63 involvement in maternal reproduction. Recent findings have elucidated the role in DNA damage response of a novel Hominidae p63 isoform, GTAp63, specifically expressed in human spermatic precursors. Thus, these findings suggest a unique strategy of p63 gene, to evolve in order to preserve the species as a guardian of reproduction. Elucidation of the biological basis of p63 function in reproduction may provide novel approaches to the control of human fertility.

Indexed as

AnimalsFemaleFertilityHumansMiceProtein IsoformsTranscription FactorsTumor Suppressor ProteinsProtein IsoformsTP63 protein, humanTranscription FactorsTumor Suppressor Proteins

Identifiers

PMID23165243
PMCPMC3562299
OpenAlexW2004662857

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.